Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study

详细信息    查看全文

• 作者：Janet K Freburger (1)
  Alan R Ellis (1)
  Abhijit V Kshirsagar (2)
  Lily Wang (1)
  M Alan Brookhart (1) (3)
  
  1. Cecil G. Sheps Center for Health Services Research ; University of North Carolina ; 725 Martin Luther King ; Jr. Blvd. ; CB# 7590 ; Chapel Hill ; NC ; 27599-7590 ; North Carolina
  2. UNC Kidney Center ; University of North Carolina ; 7024 Burnett-Womack ; CB# 7155 ; Chapel Hill ; NC ; 27599-7155 ; North Carolina
  3. Department of Epidemiology ; University of North Carolina ; 2101 McGavran-Greenberg Hall ; CB# 7435 ; Chapel Hill ; NC ; 27599-7435 ; North Carolina
  
• 关键词：Hemodialysis ; Intravenous iron ; Anemia management
• 刊名：BMC Nephrology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：15
• 期：1
• 全文大小：479 KB
• 参考文献：1. Besarab, A, Kaiser, JW, Frinak, S (1999) A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 34: pp. 21-28 CrossRef
  2. Charytan, C, Levin, N, Al-Saloum, M, Hafeez, T, Gagnon, S, Van Wyck, DB (2001) Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 37: pp. 300-307 CrossRef
  3. Coyne, DW, Kapoian, T, Suki, W, Singh, AK, Moran, JE, Dahl, NV, Rizkala, AR (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: pp. 975-984 CrossRef
  4. Kshirsagar, AV, Freburger, JK, Ellis, AR, Wang, L, Winkelmayer, WC, Brookhart, MA (2013) The comparative short-term effectiveness of iron dosing and formulations in U.S. hemodialysis patients. Am J Med 126: pp. 541 CrossRef
  5. Drueke, TB, Locatelli, F, Clyne, N, Eckardt, KU, Macdougall, IC, Tsakiris, D, Burger, HU, Scherhag, A (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: pp. 2071-2084 CrossRef
  6. Pfeffer, MA, Burdmann, EA, Chen, CY, Cooper, ME, de Zeeuw, D, Eckardt, KU, Feyzi, JM, Ivanovich, P, Kewalramani, R, Levey, AS, Lewis, EF, Mcgill, JB, McMurray, JJ, Parfrey, P, Parving, HH, Remuzzi, G, Singh, AK, Solomon, SD, Toto, R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: pp. 2019-2032 CrossRef
  7. Singh, AK, Szczech, L, Tang, KL, Barnhart, H, Sapp, S, Wolfson, M, Reddan, D (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: pp. 2085-2098 CrossRef
  8. Brewster, UC (2006) Intravenous iron therapy in end-stage renal disease. Semin Dial 19: pp. 285-290 CrossRef
  9. Parkkinen, J, von Bonsdorff, L, Peltonen, S, Gronhagen-Riska, C, Rosenlof, K (2000) Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 15: pp. 1827-1834 CrossRef
  10. Brewster, UC, Perazella, MA (2004) Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 17: pp. 57-60
  11. Bullen, JJ, Rogers, HJ, Spalding, PB, Ward, CG (2005) Iron and infection: the heart of the matter. FEMS Immunol Med Microbiol 43: pp. 325-330 CrossRef
  12. Collins, AJ, Ebben, J, Ma, JZ, Xia, H (1998) Iron dosing patterns and mortality [abstract]. J Am Soc Nephrol 9: pp. 250A
  13. Halliwell, B, Gutteridge, JM (1984) Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 219: pp. 1-14
  14. Martin-Malo, A, Merino, A, Carracedo, J, Alvarez-Lara, MA, Ojeda, R, Soriano, S, Crespo, R, Ramirez, R, Aljama, P (2012) Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 27: pp. 2465-2471 CrossRef
  15. Sevanian, A, Hochstein, P (1985) Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr 5: pp. 365-390 CrossRef
  16. Berliner, JA, Heinecke, JW (1996) The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20: pp. 707-727 CrossRef
  17. Himmelfarb, J, Stenvinkel, P, Ikizler, TA, Hakim, RM (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: pp. 1524-1538 CrossRef
  18. Brookhart, MA, Freburger, JK, Ellis, K, Wang, L, Winkelmayer, WC, Kshirsagar, AV (2013) Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Nephrol Soc 24: pp. 1151-1158 CrossRef
  19. Kshirsagar, AV, Freburger, JK, Ellis, AR, Wang, L, Winkelmayer, WC, Brookhart, MA (2013) The comparative short-term cardiovascular safety of intravenous iron dosing in hemodialysis patients. PLOS One 8: pp. e78930 CrossRef
  Researcher's Guide to the USRDS Database,2011. National Institutes of Health, NIDDK, Bethesda, MD
  20. Elixhauser, A, Steiner, C, Harris, DR, Coffey, RM (1998) Comorbidity measures for use with administrative data. Med Care 36: pp. 8-27 CrossRef
  21. Xie, X, Strickler, HD, Xue, X (2013) Additive hazard regression models: an application to the natural history of human papillomavirus. Comput Math Methods Med 2013: pp. 796270 CrossRef
  22. Lin, DY, Wei, LJ (1989) The robust inference for the proportional hazards model. J Am Stat Assoc 84: pp. 1074-1078 CrossRef
  23. Robins, JM, Hernan, MA, Brumback, B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11: pp. 550-560 CrossRef
  24. Hernan, MA, Brumback, B, Robins, JM (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11: pp. 561-570 CrossRef
  25. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/15/154/prepub
  
• 刊物主题：Nephrology; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2369

文摘

Background Recent research has reported that patients receiving bolus (frequent large doses to achieve iron repletion) versus maintenance dosing of iron have an increased short-term risk of infection, but a similar risk of cardiovascular events. We sought to determine whether these findings could be replicated using the same methods and a different data source. Methods Clinical data from 6,605 patients of a small U.S. dialysis provider merged with Medicare claims data were examined. Iron dosing patterns (bolus, maintenance, no iron) were identified during 1-month exposure periods and cardiovascular and infection-related outcomes were assessed during 3-month follow-up periods. The effects of bolus versus maintenance dosing were assessed using Cox proportional hazards regression analyses to estimate hazard ratios and semiparametric additive risk models to estimate hazard rate differences, controlling for demographic and clinical characteristics, laboratory values and medications, and comorbidities. Results 48,050 exposure/follow-up periods were examined. 13.9 percent of the exposure periods were bolus dosing, 49.3 percent were maintenance dosing, and the remainder were no iron use. All of the adjusted hazard ratios were >1.00 for the infection-related outcomes, suggesting that bolus dosing increases the risk of these events. The effects were greatest for hospitalized for infection of any major organ system (hazard ratio 1.13 (1.03, 1.24)) and use of intravenous antibiotics (hazard ratio 1.08 (1.02, 1.15). When examining the subgroup of individuals with catheters, the hazard ratios for the infection-related outcomes were generally greater than in the overall sample. There was little association between type of dosing practice and cardiovascular outcomes. Conclusions Results of this study provide further evidence of the association between bolus dosing and increased infection risk, particularly in the subgroup of patients with a catheter, and of the lack of an association between dosing practices and cardiovascular outcomes.